Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone Payments

The collaboration, launched through a multi-target discovery collaboration and license agreement, is designed to combine Merck’s global expertise in discovering novel therapeutics with Protillion’s Prot-MaP^™ on-chip antibody discovery platform, short for Protein Display on a Massively Parallel Array.

The post Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone Payments appeared first on GEN - Genetic Engineering and Biotechnology News.